tiprankstipranks
Trending News
More News >
Alphamab Oncology (HK:9966)
:9966
Hong Kong Market

Alphamab Oncology (9966) Price & Analysis

Compare
1 Followers

9966 Stock Chart & Stats


Financials

Options Prices

Currently, No data available
---

Ownership Overview

2.03%96.85%
Insiders
2.03%
Mutual Funds
― Other Institutional Investors
96.85% Public Companies and
Individual Investors

9966 FAQ

What was Alphamab Oncology’s price range in the past 12 months?
Alphamab Oncology lowest stock price was HK$2.10 and its highest was HK$9.35 in the past 12 months.
    What is Alphamab Oncology’s market cap?
    Alphamab Oncology’s market cap is HK$6.35B.
      When is Alphamab Oncology’s upcoming earnings report date?
      Alphamab Oncology’s upcoming earnings report date is Aug 28, 2025 which is in 48 days.
        How were Alphamab Oncology’s earnings last quarter?
        Alphamab Oncology released its earnings results on Mar 25, 2025. The company reported HK$0.238 earnings per share for the quarter, beating the consensus estimate of N/A by HK$0.238.
          Is Alphamab Oncology overvalued?
          According to Wall Street analysts Alphamab Oncology’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
            Does Alphamab Oncology pay dividends?
            Alphamab Oncology does not currently pay dividends.
            What is Alphamab Oncology’s EPS estimate?
            Alphamab Oncology’s EPS estimate for its next earnings report is not yet available.
            How many shares outstanding does Alphamab Oncology have?
            Alphamab Oncology has 965,141,800 shares outstanding.
              What happened to Alphamab Oncology’s price movement after its last earnings report?
              Alphamab Oncology reported an EPS of HK$0.238 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -3.096%.
                Which hedge fund is a major shareholder of Alphamab Oncology?
                Currently, no hedge funds are holding shares in HK:9966

                Alphamab Oncology Stock Smart Score

                8
                Outperform
                1
                2
                3
                4
                5
                6
                7
                8
                9
                10

                Technicals

                SMA
                Positive
                20 days / 200 days
                Momentum
                193.72%
                12-Months-Change

                Fundamentals

                Return on Equity
                9.52%
                Trailing 12-Months
                Asset Growth
                1.39%
                Trailing 12-Months

                Company Description

                Alphamab Oncology

                Alphamab Oncology, a clinical stage biopharmaceutical company, engages in the discovery, development, manufacture, and commercialization of oncology biologics. Its product pipeline includes KN046, a bispecific monoclonal antibody (BsAb) immune checkpoint inhibitor, which is in pivotal Phase III clinical trials that targets clinically-validated immune checkpoints, including programmed death ligand 1 (PD-L1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4); and KN026, a next generation anti-human epidermal growth factor receptor 2 (HER2) BsAb that is in Phase II clinical trials for treating HER2-positive breast cancers and I/II clinical trial treatment of heavily pre-treated breast cancers, as well as Phase II clinical trial for HER2-positive solid tumors. The company's product pipeline also comprises KN019, a CTLA-4-based immunosuppressant fusion protein, which is in Phase II clinical trial with potential broad applications in both auto-immune diseases and oncology treatment-induced immune disorders; and KN035, an injectable PD-L1 inhibitor that has completed phase II pivotal clinical trials for deficient mismatch repair/microsatellite instability-high solid tumors, and is in Phase III pivotal trials for biliary tract cancer. In addition, its product pipeline also includes KN052 an innovative PD-L1/OX40 bispecific antibody, which is in phase Ia/Ib clinical trial for the treatment of advanced solid tumors. The company was founded in 2008 and is headquartered in Suzhou, the People's Republic of China.
                Similar Stocks
                Company
                Price & Change
                Follow
                SinoMab Bioscience Ltd.
                Abbisko Cayman Limited
                Lepu Biopharma Co. Ltd. Class H
                HBM Holdings Ltd.
                Ascletis Pharma, Inc.
                Popular Stocks
                What am I Missing?
                Make informed decisions based on Top Analysts' activity
                Know what industry insiders are buying
                Get actionable alerts from top Wall Street Analysts
                Find out before anyone else which stock is going to shoot up
                Get powerful stock screeners & detailed portfolio analysis